New pill shows promise in early trial for tough cancers

NCT ID NCT04648254

Completed Disease control Sponsor: Qurient Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink tumors. The study is now complete, and results will help decide if Q702 should be tested in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER METASTATIC CANCER SOLID TUMOR

Contacts and locations

Locations

Atlantic Health System Hospital

Morristown, New Jersey, 07960, United States
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Northwestern University

Chicago, Illinois, 60611, United States
University of Southern California

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.